Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | BCR | P11274 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16549571 | 1.00 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL181096 | 1.00 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13664085 | 1.00 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14642922 | 1.00 | DGAT1 (0.53) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL15445166 | 0.81 | DGAT1 (0.54) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL180688 | 0.81 | DGAT1 (0.54) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL13664084 | 0.81 | DGAT1 (0.54) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL14617042 | 0.81 | DGAT1 (0.54) | DGAT1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL181168 | 0.81 | DGAT1 (0.81) | DGAT1 | |
| SCHEMBL181182 | 0.80 | DGAT1 (0.68) | DGAT1MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166204-B | Cyclic peptides as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| WO-2023084449-A1 | DIAMINOCYCLOPENTYLPYRIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | NOVARTIS AG (CH) | 2023-05-19 | — | — | WO | disclosed |